Data from EMC - Curated by Toby Galbraith - Last updated 20 April 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Adults
Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

Visit Prostate Cancer

More information

Category Value
Agency product number EMEA/H/C/001087
Orphan designation No
Date First Approved 11-12-2009
Type Medicinal product subject to medical prescription
Marketing authorisation holder Glenmark Pharmaceuticals s.r.o.

Related Content